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Abstract
Introduction:  Bacterial  resistance  burden  has  increased  in  the  past  years,  mainly  due  to  inap-
propriate  antibiotic  use.  Recently  it  has  become  an  urgent  public  health  concern  due  to  its
impact on  the  prolongation  of  hospitalization,  an  increase  of  total  cost  of  treatment  and
mortality  associated  with  infectious  disease.  Almost  half  of  the  antimicrobial  prescriptions
in outpatient  care  visits  are  prescribed  for  acute  upper  respiratory  infections,  especially  rhi-
nosinusitis,  otitis  media,  and  pharyngotonsillitis.  In  this  context,  otorhinolaryngologists  play  an
important  role  in  orienting  patients  and  non-specialists  in  the  utilization  of  antibiotics  rationally
and properly  in  these  infections.
Objectives:  To  review  the  most  recent  recommendations  and  guidelines  for  the  use  of  antibi-
otics in  acute  otitis  media,  acute  rhinosinusitis,  and  pharyngotonsillitis,  adapted  to  our  national
reality.
Methods: A  literature  review  on  PubMed  database  including  the  medical  management  in  acute
otitis media,  acute  rhinosinusitis,  and  pharyngotonsillitis,  followed  by  a  discussion  with  a  panel
of specialists.
Results:  Antibiotics  must  be  judiciously  prescribed  in  uncomplicated  acute  upper  respiratory
tract infections.  The  severity  of  clinical  presentation  and  the  potential  risks  for  evolution  to
suppurative  and  non-suppurative  complications  must  be  taken  into  ‘consideration’.
Conclusions:  Periodic  revisions  on  guidelines  and  recommendations  for  treatment  of  the  main
acute infections  are  necessary  to  orient  rationale  and  appropriate  use  of  antibiotics.  Continuous
medical education  and  changes  in  physicians’  and  patients’  behavior  are  required  to  mod-
ify the  paradigm  that  all  upper  respiratory  infection  needs  antibiotic  therapy,  minimizing  the
consequences  of  its  inadequate  and  inappropriate  use.
© 2018  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
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Como  evitar  o  uso  inadequado  de  antibióticos  nas  infecc¸ões de  vias  aéreas
superiores?  Posic¸ão de  um  painel  de  especialistas
Resumo
Introduc¸ão:  A  resistência  bacteriana  a  antibióticos  nos  processos  infecciosos  é  um  fato  cres-
cente nos  últimos  anos,  especialmente  devido  ao  seu  uso  inapropriado.  Ao  longo  dos  anos
vem se  tornando  um  grave  problema  de  saúde  pública  devido  ao  prolongamento  do  tempo
de internac¸ão,  elevac¸ão  dos  custos  de  tratamento  e  aumento  da  mortalidade  relacionada  às
doenc¸as infecciosas.  Quase  a  metade  das  prescric¸ões  de  antibióticos  em  unidades  de  pronto
atendimento  é  destinada  ao  tratamento  de  alguma  infecc¸ão  de  vias  aéreas  superiores,  espe-
cialmente  rinossinusites,  otite  média  aguda  supurada  e  faringotonsilites  agudas,  sendo  que  uma
significativa  parcela  dessas  prescric¸ões  é  inapropriada.  Nesse  contexto,  os  otorrinolaringologis-
tas têm  um  papel  fundamental  na  orientac¸ão  de  pacientes  e  colegas  não  especialistas,  para  o
uso adequado  e  racional  de  antibióticos  frente  a  essas  situac¸ões  clínicas.
Objetivos:  Realizar  uma  revisão  das  atuais  recomendac¸ões  de  utilizac¸ão  de  antibióticos  nas
otites médias,  rinossinusites  e  faringotonsilites  agudas  adaptadas  à  realidade  nacional.
Método: Revisão  na  base  PubMed  das  principais  recomendac¸ões  internacionais  de  tratamentos
das infecc¸ões  de  vias  aéreas  superiores,  seguido  de  discussão  com  um  painel  de  especialistas.
Resultados:  Os  antibióticos  devem  ser  utilizados  de  maneira  criteriosa  nas  infecc¸ões  agudas  de
vias aéreas  superiores  não  complicadas,  a  depender  da  gravidade  da  apresentac¸ão  clínica  e  dos
potenciais  riscos  associados  de  complicac¸ões  supurativas  e  não  supurativas.
Conclusões:  Constantes  revisões  a  respeito  do  tratamento  das  principais  infecc¸ões  agudas  são
necessárias  para  que  sejam  tomadas  medidas  coletivas  no  uso  racional  e  apropriado  de  antibióti-
cos. Somente  com  orientac¸ão  e  transformac¸ões  no  comportamento  de  médicos  e  pacientes  é
que haverá  mudanc¸as  do  paradigma  de  que  toda  infecc¸ão  de  vias  aéreas  superiores  deva  ser
tratada antibióticos,  minimizando  por  consequência  os  efeitos  de  seu  uso  inadequado.
© 2018  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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Introduction
Bacterial  resistance  to  antibiotics  in  infectious  processes  has
been  increasing  in  recent  years  and  has  become  a  serious
public  health  problem.1
In  October  2017,  the  World  Health  Organization  (WHO)
stated  that  bacterial  resistance  to  antibiotics  is  one  of
the  main  health  problems  worldwide,  as  it  prolongs  hos-
pital  length  of  stay,  increases  treatment  costs  and,  even
more  seriously,  considerably  increases  mortality  related  to
infectious  diseases.2 According  to  the  WHO,  inappropriate
antibiotic  use  is  considered  the  main  reason  for  the  gen-
eration  of  bacterial  resistance  to  antibiotics.  In  developed
countries  such  as  the  USA  and  Canada,  it  is  estimated  that
30--50%  of  antibiotic  prescriptions  are  inappropriate.3--5 Fur-
thermore,  approximately  50%  of  all  antibiotic  prescriptions
aim  at  the  treatment  of  upper  respiratory  infections,  espe-
cially  rhinosinusitis,  suppurative  acute  otitis  media,  and
acute  pharyngotonsillitis.4 In  this  context,  the  role  of  the
otorhinolaryngologist  is  crucial  when  advising  patients  and
non-specialists  regarding  the  adequate  and  rational  use  of
antibiotics,  particularly  for  these  clinical  conditions.3,6,7 A
broad  review  of  indications  and  forms  of  antibiotic  use  is
required  for  the  very  diverse  infectious  conditions,  with
evidence-based  collective  actions.  Hence,  several  countries
have  adopted  public  policies  to  considerably  reduce  inad-
equate  antibiotic  prescriptions.  In  one  such  example,  the
National  Action  Plan  to  fight  antibiotic-resistant  bacteria,
was  launched  in  the  United  States  in  2015,  aiming  to  reduce
by  50%  inadequate  antibiotic  prescription  by  2020.4
The  present  document  reflects  the  concern  of  the  Brazil-
ian  Association  of  Otorhinolaryngology  and  Cervical-Facial
Surgery  (ABORL-CCF)  to  adequately  guide  physicians  on  the
appropriate  antibiotic  prescription  in  cases  of  acute  otitis
media,  acute  rhinosinusitis  and  acute  pharyngotonsillitis,
aiming  to  change  the  behavior  of  physicians  and  patients  in
order  to  break  the  paradigm  that  all  upper  respiratory  infec-
tions  should  be  treated  with  antibiotics,  thus  minimizing  the
effects  of  their  inappropriate  use.
Acute Otitis Media
Acute  otitis  media  (AOM)  is  a  common  disease  in  early  child-
hood  (with  a  peak  incidence  between  6  months  and  2  years),
but  it  also  affects  older  children  and,  less  commonly,  ado-
lescents  and  adults.
To  attain  the  diagnosis,  it  should  be  considered  that
hyperemia,  diminished  tympanic  membrane  translucency  or
the  presence  of  retropharyngeal  fluid  alone,  without  bulging
or  otorrhea,  are  not  signs  that  differentiate  AOM.  Tym-
panic  membrane  bulging  is  the  most  reliable  finding.8 AOM
caused  by  pneumococcus  is  more  associated  with  impor-
tant  tympanic  membrane  alterations  (mainly  bulging),  fever
and  otalgia,  whereas  that  caused  by  H.  influenzae  is  more
associated  with  ocular  symptoms  (purulent  conjunctivitis).9
Pathogenic  bacteria  are  isolated  in  approximately  70%
of  cases  of  AOM,  including  Haemophilus  influenzae, Strep-
tococcus  pneumoniae, and  Moraxella  catarrhalis. The
pneumococcus,  previously  the  most  prevalent  agent,  has
been  supplanted  by  H.  influenzae  in  most  countries  that
have  implemented  mass  vaccination  of  the  population,  such
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s  in  the  USA.10 Although  we  do  not  have  national  data
n  middle  ear  secretion  culture  in  cases  of  AOM,  a  recent
razilian  study  has  demonstrated  an  increase  in  the  isola-
ion  of  non-typeable  H.  influenzae  and  a reduction  of  S.
neumoniae  in  the  rhinopharynx  of  children  that  received
he  10-valent  pneumococcal  conjugate  vaccine,  suggesting
hat  the  same  process  that  occurred  in  the  USA  after  the
ntroduction  of  mass  vaccination  may  also  be  occurring  in
razil.11
Approximately  30%  of  middle  ear  cultures  yield  no  bac-
erial  isolates  or  show  the  presence  of  viruses,  such  as
nfluenza,  parainfluenza,  rhinovirus  and  respiratory  syncy-
ial  virus,  reinforcing  the  important  role  of  viruses  in  the
tiology  of  AOMs.
In  the  USA,  antibiotic  prescription  for  treatment  of  child-
ood  AOM  is  more  frequent  than  for  any  other  infectious
isease.  It  is  estimated  that  more  than  80%  of  the  diag-
osed  cases  are  immediately  treated  with  antibiotics  in  most
ountries,  but  for  rare  exceptions,  as  in  the  Netherlands
31.2%  of  cases).12,13
The  natural  history  of  non-severe  AOMs  shows  that  the
ure  of  this  condition  usually  occurs  regardless  of  the  use  of
ntibiotics.  Fortunately,  non-severe  cases  represent  the  vast
ajority  of  patients  that  seek  pediatric  medical  offices  or
mergency  care  units.  Although  there  is  indeed  an  additional
enefit  in  prescribing  antibiotics  to  resolve  the  AOM  picture,
his  benefit  is  a  modest  one,  increasing  the  resolution  rate
y  only  12--14%  when  compared  to  placebo  (92--94%  with  ATB
se  vs.  80%  without  ATB  use).  Therefore,  7--9  children  with
OM  need  to  be  treated  to  obtain  the  additional  benefit  of
ntibiotic  use  in  one  of  them.14
A  recent  meta-analysis  that  evaluated  pain  reduction
ith  antibiotic  use  in  AOM  through  an  analog  scale  did  not
how  a  significant  reduction  when  compared  to  placebo  in
he  first  24  h,  with  a  beneficial  effect  (although  not  clinically
ignificant)  appearing  only  after  the  2nd  day  of  treatment.
or  the  specific  assessment  of  pain  reduction,  the  most
avorable  Number  Needed  to  Treat  (NNT)  occurs  at  the  end
f  10--12  days  of  treatment,  when  it  reaches  7  (NNT  =  20
etween  the  2nd  and  3rd  days;  NNT  =  16  between  the  4th
nd  7th  days).15
Antibiotics  have  a  beneficial  effect  in  reducing  effu-
ion  up  to  6  weeks  after  the  end  of  treatment,  preventing
arly  recurrence  of  AOM  and  perforation  onset,  but  they
re  all  are  clinically  modest.  However,  antibiotic  use  does
ot  prevent  more  serious  complications,  or  the  presence  of
ffusion  or  late  recurrences  (after  3  months).  On  the  other
and,  adverse  effects  such  as  vomiting,  diarrhea  and  skin
ash  are  significantly  more  frequent  in  children  who  receive
ntibiotics.15
In  two  studies  that  performed  culture  by  tympanic  mem-
rane  puncture  before  and  after  the  treatment,  a  more
ccurate  way  to  diagnose  and  evaluate  bacteriological
ure,16 3--7%  of  patients  who  had  negative  culture  between
ay  3  and  day  7  failed  to  respond  to  the  antibiotic.  On  the
ther  hand,  of  those  who  maintained  a  positive  culture,  the
ailure  rate  was  37--38%,  which  means  that  62--63%  of  the
atients  achieved  clinical  cure,  even  while  maintaining  a
ositive  culture  between  day  3  and  day  7.16,17Much  of  the  criticism  aimed  at  the  evidence  of  the  small
ffect  of  antibiotics  is  based  on  the  possibility  of  diagnostic
rror  when  including  children  in  the  clinical  trials  without
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he  disease  or  without  bacterial  AOM.  The  definitive  diag-
osis  of  AOM  is  based  on  otoscopy,  which  in  young  children
an  be  extremely  difficult.12
reatment
he  use  of  analgesics  and  antipyretics  should  be  immedi-
te,  since  antibiotics  take  up  to  48  h  to  relieve  the  picture
f  fever  and  otalgia.  Among  the  most  commonly  used
nalgesics  are  dipyrone,  acetaminophen  (paracetamol)  and
buprofen.
Because  of  the  greater  benefit  of  using  antibiotics  on
ome  occasions,  the  American  Academy  of  Pediatrics  recom-
ends  the  use  of  antibiotics  in  the  following  situations18,19:
 Children  younger  than  6  months.
 Children  older  than  6  months  with  severe  disease
(moderate  to  severe  otalgia  for  more  than  48  h,  or  tem-
perature  ≥  39 ◦C).
 Bilateral  AOM  (NNT  =  5).
 Presence  of  otorrhea  (NNT  =  3).
As  for  the  cases  that  require  treatment  with  antibi-
tics,  these  should  cover  the  most  commonly  involved
acteria.  The  recommended  treatment  for  uncomplicated
ases  is  amoxicillin  (45  mg/kg/day,  divided  into  two  or
hree  doses),  which  may  be  associated  with  beta-lactamase
nhibitors  in  patients  with  aggravating  comorbidities  or  sus-
ected/confirmed  resistant  infections  (for  instance,  culture
roving  resistance,  previous  poor  outcome  with  the  drug,
ecent  antibiotic  use)  (Table  1).18,20,21The  American  Academy  of  Pediatrics  recommends  the
se  of  amoxicillin  at  doses  of  90  mg/kg/day,  associated  or
ot  with  potassium  clavulanate.18 However,  the  intermedi-
te  resistance  of  pneumococcus  in  our  country  is  still  low
t
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Table  1  Antibiotics  recommended  for  the  treatment  of  acute  oti
Initial  antibiotic  treatment  at  the  time  of  diagnosis  or  after
observation
An
First-line  treatment  Alternative  treatment  Fir
Amoxicillin
(45--90  mg/kg/day)
Cefuroxime  (30  mg/kg/day)
(In  allergic  reaction  to
non-type  I  penicillin)
Am
(45
am
6.4
cla
Or Or
Amoxicillin--clavulanatea
(45--90  mg/kg/day  of
amoxicillin  with
6.4  mg/kg/day  of
clavulanate)
Clarithromycin  (15  mg/kg
weight/day)
(In allergic  reaction  to  type  I
penicillin)
Ce
(50
for
Ceftriaxone  (50  mg/kg/day  IM
or IV  for  1--3  days)
a It can be considered in patients that received amoxicillin in the pre
b Find an otorhinolaryngologist for tympanocentesis/drainage/secretPiltcher  OB  et  al.
nd  thus,  this  measure  is  not  justified  as  the  first  option  in
razil.22
Regarding  treatment  duration,  the  indication  of  using
he  antibiotic  for  at  least  10  days  remains,  especially
or  more  severely  affected  patients  with  the  risk  charac-
eristics  that  indicate  the  need  for  antibiotic  treatment
for  instance,  bilateral  disease  and  otorrhea).23 Initial
tudies  even  showed  some  optimism  regarding  shorter
reatments  (5--7  days),  with  the  potential  advantages  of  pro-
ucing  fewer  gastrointestinal  side  effects  and  decreasing
he  emergence  of  resistant  strains.  However,  recent  stud-
es  have  shown  the  superiority  of  the  10-day  treatments
ver  shorter  ones,  with  the  same  incidence  of  adverse
ffects.23
For  patients  with  non-severe  allergy  to  penicillins,
econd-  or  third-generation  cephalosporins,  clindamycin
nd  macrolides,  especially  clarithromycin,  may  be  used.
zithromycin  and  cefaclor  should  not  be  used,  due  to  the
igh  resistance  index.  Sulfa  drugs  should  be  avoided  due  to
he  low  therapeutic  efficacy  in  children.24
For  adults,  the  antibiotic  therapy  recommendations  are
imilar  to  the  options  used  in  acute  bacterial  rhinosinusitis
Table  2).
Complications  of  AOMs  may  include  tympanic  membrane
upture,  mastoiditis,  meningitis,  subperiosteal  abscesses,
ntracranial  abscesses,  subdural  abscesses,  dural  sinus
hrombosis,  labyrinthitis,  petrositis,  facial  paralysis  and
epsis.  It  is  noteworthy  that  the  early-onset  of  antibiotic
herapy  does  not  prevent  the  occurrence  of  suppurative
omplications,  since  most  individuals  with  complications
ere  receiving  some  type  of  antibiotic.  In  the  presence  of
omplications,  tympanocentesis  (with  or  without  the  inser-
ion  of  a  ventilation  tube)  should  be  performed  whenever
ossible,  aiming  to  aspirate  secretions  and  collect  material
or  culture.  Fig.  1  summarizes  the  treatment  flowchart  for
atients  with  AOM.
tis  media.22
tibiotic  treatment  after  48--72  h  of  initial  treatment  failure
st-line  treatment  Alternative  treatment
oxicillin--clavulanate
--90  mg/kg/day  of
oxicillin  with
 mg/kg/day  of
vulanate)
Ceftriaxone  3  days,  or
Clindamycin
(30--40  mg/kg/day)  with
or without  second-  or
third-generation
cephalosporin
Vancomycin  IV
ftriaxone
 mg/kg/day  IM  or  IV
 3  days)
Clindamycin  +  second-  or
third-generation
cephalosporin
Consult  specialist
Tympanocentesisb
vious 30 days or have otitis-conjunctivitis syndrome.
ion collection for culture and antibiogram.
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Table  2  Treatment  indicated  by  the  Expert  Opinion  of  the  Brazilian  Academy  of  Rhinology  for  the  treatment  of  uncomplicated
bacterial ARS  and  extrapolated  to  the  treatment  of  bacterial  otitis  media  in  adults.
Main  antibiotic  options  Dose  and  posology  Time  of  treatmenta Considerations
Amoxicillin  500  mg,  3×/day  7--14  days  Preferred  antibiotic  agent  in  patients  with  no
suspected  or  confirmed  bacterial  resistance,  with
no prior  use  of  antibiotics  in  the  last  30  days  for
the same  clinical  picture.
Amoxicillin  875  mg,  2×/day 7--14  days Preferred  antibiotic  agent  in  patients  with  no
suspected  or  confirmed  bacterial  resistance,  with
no prior  use  of  antibiotics  in  the  last  30  days  for
the same  clinical  picture.
Amoxicillin-Clavulanate  500  mg/125  mg,  3×/day 7--14  days Indicated  for  -lactamase  producing  bacteria.
Diarrhea  occurs  in  1--10%  cases
Amoxicillin-Clavulanate  875  mg/125  mg,  2×/day 7--14  days Indicated  for  -lactamase  producing  bacteria.
Diarrhea  occurs  in  1--10%  cases
Cefuroxime  Axetil  250--500  mg,  2×/day  7--14  days  Spectrum  of  action  similar  to  that  of
amoxicillin-clavulanate.  An  option  in  cases  of
non-anaphylactic  allergic  reactions  to  penicillins.
Evidence  of  increased  induction  of  bacterial
resistance  in  relation  to  penicillins.25
Option  in  those  allergic
to  -lactams
Dose  and  posology  Time  of  treatmenta Considerations
Clarithromycin  500  mg,  2×/day 7--14  days Consider  high  resistance.  Contraindication  for  the
concomitant  use  of  statins
Levofloxacin  500  mg,  1×/day 5--7  days The  Food  and  Drug  Administration  (FDA)
determines  that  the  prescription  of
fluoroquinolones  to  patients  with  bacterial  ARS
should  occur  only  when  there  are  no  other
antibiotic  treatment  options,  as  the  risks
outweigh  the  benefits  in  these  cases.b
Levofloxacin  750  mg,  1×/day  5--7  days
Moxifloxacin  400  mg,  1×/day  5--7  days
Doxycycline  100  mg,  2×/day  7--14  days  Photosensitivity  reaction
Options  in  therapeutic
failure  casesc
Dose  and  posology  Time  of  treatment  Considerations
Amoxicillin  1000  mg,  3×/day  7--14  days  Exception  conduct  proposed  by  some  specialists,
based  on  microbiological  knowledge,  without
proven  clinical  evidence.  Consider  exacerbated
gastrointestinal  effects.
High-dose
Amoxicillin  +  Clavulanate
2000  mg  Amx/125  mg
Clav,  2×/day
7--14  days  Exception  conduct  proposed  by  some  specialists,
based  on  microbiological  knowledge,  without
proven  clinical  evidence.  Consider  exacerbated
gastrointestinal  effects.
Levofloxacin  750  mg,  1×/day  5--7  days  The  Food  and  Drug  Administration  (FDA)
determines  that  the  prescription  of
fluoroquinolones  to  patients  with  bacterial  ARS
should  occur  only  when  there  are  no  other
antibiotic  treatment  options,  as  the  risks
outweigh  the  benefits  in  these  cases.b
Moxifloxacin  400  mg,  1×/day  5--7  days
Clindamycin  300  mg,  3--4×/day  7--10  days  Option  in  case  of  suspected  infection  by  anaerobic
bacteria  or  S.  aureus.  Take  with  300  mL  of  water
due to  risk  of  esophageal  lesion.  Precaution:  risk
of membranous  pseudocolitis  and  diarrhea  caused
by Clostridium  difficile.
a There is a tendency to use antibiotic therapy for less time with equal effectiveness aiming to minimize side effects and bacterial
resistance generation.
b It should be considered individually, according to disease severity.
c Absence of response or clinical worsening after 48--72 h of treatment.
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Figure  1  Flowchart  of  the  diagnosis  an
Table  3  Cardinal  symptoms  of  rhinosinusitis.
Main  symptoms Associated  symptoms
Rhinorrhea  Facial  pain
Nasal  obstruction  Changes  in  olfaction
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cute Rhinosinusitis
cute  rhinosinusitis  (ARS)  is  inflammation  of  the  nasal
ucosa  and  paranasal  sinuses  that  usually  presents  with
wo  or  more  of  the  following  symptoms,  such  as  rhinor-
hea  and/or  nasal  obstruction  (with  one  of  them  being
andatory),  facial  pain  and  olfactory  alterations.  In  pedi-
tric  patients,  coughing  is  a  rather  common  symptom,  more
ommon  than  olfactory  alterations  (Table  3).26
The  American  guidelines  for  rhinosinusitis  (2015)  point
ut  that  purulent  rhinorrhea  is  the  most  reliable  symp-
om  for  its  diagnosis.  Thus,  the  presence  of  two  or  more
ymptoms  is  considered  for  the  diagnosis  of  ARS,  with  the
resence  of  purulent  rhinorrhea  being  mandatory,  associ-
ted  with  nasal  congestion  and/or  facial  pain.27
iral  or  Bacterial?
RS  cases  usually  start  as  a  viral  infection.  Most  of  these
ases  show  spontaneous  resolution  within  7--10  days,  with
lear  improvement  after  5  days  of  evolution.  Only  0.5--2%
f  the  cases  show  evolution  to  bacterial  ARS  in  adults,  and
--13%  of  cases  in  children.28
According  to  the  American  guidelines  for  rhinosinusitis
2015),  we  should  consider  the  diagnosis  of  acute  bacte-
p
i
c
rd  treatment  of  acute  otitis  media.
ial  rhinosinusitis  (ABRS)  when  the  cardinal  symptoms  persist
or  more  than  10  days,  with  no  evidence  of  improvement  in
he  short  term,  or  even  symptom  worsening  after  a  period
f  initial  improvement,  which  is  called  double-worsening
Fig.  2).27
According  to  the  Brazilian  (2015)  and  European  Guide-
ines  for  Rhinosinusitis  (EPOS  2012  --  European  Position
aper  on  Rhinosinusitis  and  Nasal  Polyps),  cases  that  do
ot  clearly  show  as  viral  (duration  up  to  10  days,  with
vident  improvement  after  the  5th  day)  are  called  post-
iral.  Among  post-viral  pictures,  the  diagnosis  of  ABRS  should
e  considered  in  patients  with  symptoms  for  more  than
0  days  and  who  have  at  least  3  of  the  following  criteria
Figs.  3  and  4)26,29:
 Worsening  after  a  milder  initial  phase.
 Predominantly  unilateral  rhinorrhea  and/or  purulent  pos-
terior  rhinorrhea.
 Severe  facial  pain,  mainly  unilateral.
 Fever  ≥  38.3 ◦C.
 Increased  values  of  inflammatory  markers  (ESR,  CRP)  (in
practice,  blood  tests  are  rarely  required  for  the  differen-
tial  diagnosis  of  acute  rhinosinusites).
arning  signs
he  complications  of  ARS  are  extremely  rare.  They  occur
hen  the  infection  extends  beyond  the  borders  of  the
aranasal  sinuses.  It  is  estimated  that  1 complication  occurs
n  every  12,000  episodes  of  ARS  in  children,  and  1  compli-
ation  for  every  32,000  episodes  in  adults,  mandatorily
equiring  the  use  of  antibiotics  in  these  situations.30
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Figure  2  Evolution  of  acute  bacterial  rhinosinusitis  after  a  viral  illness.
Adapted  from  the  American  Guidelines  for  Rhinosinusitis,  2015.
Acute viral rhinosinusitis
Acute post-viral 
rhinosinusitis
Acute Bacterial Rhinosinusitis
Figure  3  Representativeness  of  acute  viral  rhinosinusitis  develo
bacterial rhinosinusitis,  according  to  EPOS  (2012).
Figure  4  Evolution  of  acute  rhinosinusitis.
Modified  from  EPOS  2012.
Table  4  Warning  signs  for  ARS  complications.
Orbital  changes
Visual  changes
Intense  frontal  pain
Frontal  bulging
Signs  of  meningitis
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Decrease  in  the  level  of  consciousness
Some  warning  signs  should  be  observed,  which  indicate
the  possible  presence  of  ARS  complications  (Table  4).Treatment
Symptomatic  treatment  is  extremely  important  for  quality
of  life  improvement  and  can  be  instituted  in  all  ARS  cases.
i
v
4
sping  into  acute  post-viral  rhinosinusitis  or,  eventually,  acute
he  medication  should  be  chosen  according  to  the  patient’s
ost  intense  symptoms.  Hence,  the  physician  should  per-
onalize  the  treatment  for  each  patient,  avoiding  the  use  of
‘standard  prescriptions’’.
Analgesics,  non-steroidal  anti-inflammatory  drugs
NSAIDs)  and  topical  or  systemic  decongestants  are  good
herapeutic  options,  as  they  treat  symptoms  that  bring  great
iscomfort,  such  as  pain,  malaise,  and  nasal  obstruction.
he  symptomatic  relief  produced  by  these  medications  may
educe  the  need  for  antibiotics  in  such  situations.  However,
uch  medications  should  be  used  sparingly,  since  NSAIDs  and
opical  and  systemic  decongestants  are  associated  with  a
igh  rate  of  significant  side  effects.27
Nasal  lavage  with  saline  solution  or  hypertonic  solution
s  recommended  for  the  treatment  of  ARS,  whether  viral  or
acterial,  as  it  contributes  to  the  reduction  of  symptoms  and
aster  disease  resolution.  Currently,  there  are  conflicting
ata  on  the  use  of  the  hypertonic  solution,  in  addition  to
eing  more  uncomfortable  for  the  patient,  as  it  can  cause
 burning  sensation  and  lower  treatment  adherence.  Thus,
asal  lavage  with  isotonic  solutions  has  been  more  often
ecommended  for  this  purpose.30,31
cute Viral Rhinosinusitis
elargonium  sidoides
ntiviral  medications  can  be  used  in  acute  viral  rhinosi-
usitis,  such  as  Pelargonium  sidoides.  This  phytomedicine
ncreases  the  immune  response  to  infection  by  decreasing
iral  replication.  Ideally,  it  should  be  used  within  the  first
8  h  of  the  viral  picture  onset.  Patients  taking  anticoagulants
hould  avoid  using  it.29
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Table  5  National  profile  of  antibiotic  sensitivity  according
to some  isolated  agents.
Microbiota  Drug  Sensitivity
Streptococcus  spp.
(except  in
meningitis)
Penicillin  93%  (>5  years)
Sulfamethoxazole/
Trimethoprim
66%
Haemophilus
influenzae
Ampicillin  86.5%
Sulfamethoxazole/ 75%
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opical  Corticosteroids  (CS)
opical  CS  have  a  high  local  anti-inflammatory  effect,  with  a
ow  rate  of  side  effects.  They  aid  in  reducing  nasal  mucosa
dema,  improving  obstructive  symptoms  and  contributing
o  the  patency  of  the  sinus  drainage  ostia.  They  also  reduce
ucus  production  and  neurogenic  inflammation,  decreasing
ymptoms  such  as  sneezing  and  nasal  pruritus.
The  European  guidelines  (EPOS  2012)  recommend  the
se  of  topical  CS  in  post-viral  and  bacterial  acute  rhinosi-
usitis  with  a  double  dose,  aiming  at  the  above  mentioned
eneficial  effects.29 The  American  guidelines  (2015),  how-
ver,  consider  the  use  of  topical  CS  even  in  acute  viral
hinosinusitis.29
cute Bacterial Rhinosinusitis
opical  Corticosteroids
n  cases  of  acute  bacterial  rhinosinusitis  (ABRS),  the  use  of
opical  CS  is  recommended  due  to  the  abovementioned  anti-
nflammatory  effects.  Moreover,  there  is  evidence  that  the
se  of  topical  CS  has  similar  efficacy  to  the  use  of  antibi-
tic  alone  in  milder  ABRS  cases,  which  could  spare  the  use
f  antibiotics.  This  practice  should  be  encouraged  to  avoid
he  abusive  use  of  antibiotics  in  milder  situations.  Similar
o  post-viral  rhinosinusitis,  double  doses  of  topical  cortico-
teroids  tend  to  produce  more  significant  beneficial  effects,
lthough  the  benefit  of  treatment  is  still  a  modest  one.27,29
In  patients  with  severe  symptoms,  especially  pain,  oral
orticosteroids  may  be  prescribed  for  a  short  period.29 It  is
mportant  to  note  that  intramuscular  long-lasting  corticos-
eroid  injections  are  not  recommended.
ntibiotics
or  patients  who  meet  the  criteria  for  ABRS  (approximately
.5--2%  of  total  AVRS),  the  use  of  antibiotics  may  be  rec-
mmended.  According  to  EPOS,  mild  cases  can  be  initially
reated  only  with  measures  recommended  for  post-viral  ARS
nd  reevaluated  within  48--72  h,  whereas  in  more  severe
ases  they  should  receive  antibiotic  therapy.29
According  to  the  American  guidelines,  the  doctor  may
hoose  to  immediately  prescribe  an  antibiotic  for  ABRS  or
erform  an  initial  treatment  of  ABRS  with  delayed  prescrip-
ion  of  antibiotics  (watchful  waiting).  In  this  case,  patients
tart  the  treatment  with  topical  CS  and  nasal  lavage  with
aline  solution,  but  receive  the  prescription  for  the  antibi-
tic,  although  they  would  be  advised  to  wait  to  start  its
se  (‘‘wait-and-see’’  prescription).  The  antibiotic  should  be
tarted  if  there  is  no  improvement  in  7  days  or  if  there  is
orsening  of  the  condition  at  any  time.  It  is  important  to
mphasize  that  this  approach  should  be  used  only  in  cases
hat  meet  the  criteria  for  ABRS  and  should  not  be  used  in
iral  cases  or  even  those  with  diagnostic  doubt.
The  bacterial  agents  most  often  implicated  in  ABRS  are:
.  pneumoniae, H  influenzae  and  M.  catarrhalis. National
ata  on  antibiotic  sensitivity  are  shown  in  Table  5.
Based  on  the  national  sensitivity  profile  of  these
icroorganisms,  the  recommendation  for  the  choice  of
i
t
s
cTrimethoprim
Source: SIREVA 2014.
ntimicrobial  medication  is  shown  in  Tables  2  and  6. Fig.  5
hows  a  flowchart  for  the  rational  evaluation  of  antibiotic
se  in  the  most  diverse  presentations  of  ARS.
The  Brazilian  guidelines  and  EPOS  2012  classify  this  situ-
tion  as  post-viral  ARS,  and  post-viral  conditions  that  meet
 of  the  following  criteria  are  considered  bacterial:
 Worsening  after  a  milder  initial  phase.
 Predominantly  unilateral  rhinorrhea  and/or  frankly  puru-
lent  post-nasal  drip.
 Severe  local  pain,  mainly  unilateral.
 Fever  >  38 ◦C.
 Increased  inflammatory  markers  (ESR,  CRP).
cute Pharyngotonsillitis
cute  pharyngotonsillitis  is  a  disease  characterized  by  signs
nd  symptoms  related  to  the  inflammation  of  the  phar-
nx  and  Waldeyer’s  lymphatic  ring  structures  and  may  be
ssociated  with  a  wide  range  of  regional  and/or  systemic
ymptoms.
Most  cases  of  pharyngotonsillitis  is  caused  by  viruses  (70%
f  cases),  usually  with  diffuse  and  mild  odynophagia,  low
r  no  fever,  coughing,  hoarseness,  nasal  congestion,  rhinor-
hea,  presence  of  ulcerated  or  vesicular  lesions  on  the  oral
ucosa,  insidious  evolution,  among  others.32,33
As  for  the  bacterial  cases,  which  correspond  to  a  lower
ercentage  in  all  age  groups  (less  than  30%  of  the  cases),  usu-
lly  show  more  severe  odynophagia,  high  fever  (>38.5 ◦C),
ymph  nodes  larger  than  1  cm,  tonsillar  and  pharyngeal
dema  and  exudate,  palatal  petechia,  scarlatiniform  rash,
solated  abdominal  pain  and  abrupt  symptom  onset.  Among
he  main  bacterial  agents  involved  in  acute  pharyngoton-
illitis,  S.  pyogenes  (Lancefield  group  A  beta-hemolytic
treptococcus)  stands  out  because  of  its  high  prevalence  in
he  age  range  of  3--15  years  (up  to  2/3  cases),  more  inva-
ive  forms  with  systemic  effects  and,  especially,  its  risk  of
eveloping  rheumatic  fever.
Due  to  its  relevance  for  the  treatment,  the  differentia-
ion  of  acute  pharyngotonsillitis  caused  by  S.  pyogenes  plays
n  important  role.  For  etiological  determination,  microbial
dentification  through  oropharynx  culture  is  still  considered
he  gold  standard  test  (with  sensitivity  between  60--90%  and
pecificity  between  65--95%).  Considering  the  non-negligible
osts  for  its  performance,  as  well  as  the  time  required
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Table  6  Antibiotics  recommended  in  the  treatment  of  ABRS  in  the  pediatric  population.
Initial  antibiotic  treatment  at  the  time  of  diagnosis  or  after
observation
Antibiotic  treatment  after  48--72  h  of  initial  treatment
failure
First-line  treatment  Alternative  treatment  First-line  treatment  Alternative  treatment
Amoxicillin
(45--90  mg/kg/day)
Cefuroxime
(30  mg/kg/day)
(In  allergic  reaction  to
non-type  I  penicillin)
Amoxicillin--clavulanate
(45--90  mg/kg/day  of
amoxicillin  with
6.4  mg/kg/day  of
clavulanate)
Ceftriaxone  3  days,  or
Clindamycin
(30--40  mg/kg/day)  with
or without  second-  or
third-generation
cephalosporin
Vancomycin  IV
Or Or
Amoxicillin--clavulanatea
(45--90  mg/kg/day  of
amoxicillin  with
6.4  mg/kg/day  of
clavulanate)
Clarithromycin
(15  mg/kg  weight/day)
Sulfamethoxazole/Trimethoprim
(In  allergic  reaction  to
type  I  penicillin)
Ceftriaxone
(50  mg/kg/day  IM  or  IV
for 3  days)
Clindamycin  +  second-  or
third-generation
Cephalosporin
Ceftriaxona
(50 mg/kg/day  IM  or  IV
for 1--3  days)
Consult  specialist
a It can be considered as an option in children who received amoxicillin in the last 30 days or in areas with high bacterial resistance to
amoxicillin.
< 4 weeks with 2 or + symptoms: 
rhinorrhea / obstruction + 
facial pain / hyposmiatt
 AVRS  ABRS 
Duration and 
evolution
< 10 days AND 
improvement after 5th
No improvement after 10
 days OR worsening
 after 5th day
ATB
Always: Nasal lavage + 
options: analgesics, 
NSAIDs, decongestants,
 Pelargonium sidoides,
Always: Nasal lavage AND 
nasal CS + Options: 
analgesics, NSAIDs,
 decongestants
 No Yes
First option AMX 
or AMX-CLAV
Watchful waiting
Wait-n-see prescription
Use ATB if there is no 
improvement or 
if there is worsening
Alternatives: 
See Tables 6 and 7
Figure  5  Evaluation  flow  chart  according  to  the  presence  of  signs  and  symptoms,  aimed  to  elucidate  the  probable  etiological
diagnosis and  its  treatment.
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Table  7  Probability  of  pharyngotonsillitis  by  S.  pyogenes
according  to  the  modified  Centor  criteria  (McIsaac).33
Modified  Centor  criteria  (McIsaac)
Variable  Score
Fever  >  38 ◦C  +1
No coughing +1
Anterior  cervical
adenopathy  >  1  cm
+1
Tonsillar  exudate  or
edema
+1
Age  3--14  years  +1
Age 15--44  years  0
Age ≥  45  years  −1
Total  score  Probability  of  S.  pyogenes
≤0  points  ∼2.5%
1 points  ∼6--7%
2 points  ∼15%
3 points  ∼30--35%
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o  obtain  results  (48--72  h),  such  factors  limit  its  routine
se  in  cases  of  acute  pharyngotonsillitis.  An  alternative
est  is  the  rapid  strep  test  (RST)  to  detect  streptococcal
ntigens,  which  has  sensitivity  and  specificity  similar  to
hose  of  culture  tests.33,34 Although  it  has  a  great  advan-
age  regarding  the  time  to  obtain  the  results  (approximately
5  min),  this  test  still  has  a  relatively  high  cost,  which  makes
t  impossible  to  apply  this  routine  test  at  public  services.
dditionally,  positive  results  in  these  tests  do  not  allow  the
ifferentiation  of  the  etiologic  cause  in  chronic  carriers  of
.  pyogenes.
In  daily  practice,  other  validated  and  reproducible  clin-
cal  methods  in  different  age  groups  have  been  used  to
dentify  the  probability  of  S.  pyogenes  infection.  One  is  the
odified  Centor  clinical  score  (McIsaac),  which  includes  his-
ory  and  physical  examination  characteristics  (Table  7).
Although  the  modified  Centor  score  is  one  of  the  most
requently  used  worldwide,  it  still  lacks  good  sensitivity  for
etection,  with  moderate  positive  predictive  value.  Despite
hese  limitations,  the  two  scoring  ends  (≤1  or  ≥4  points)
ave  been  used  as  discriminators  of  low  probability  and
igh  probability  of  infection  by  S.  pyogenes,  respectively.
herefore,  for  patients  with  a  low  probability  of  streptococ-
al  infection  (total  score  ≤  1  in  the  modified  Centor  score),
s  well  as  in  the  more  likely  clinical  settings  (score  ≥  4  in
he  modified  Centor  score),  there  would  be  no  need  to  rou-
inely  use  the  test.34 Patients  with  a  moderate  probability
f  streptococcal  infection  (total  score  of  2--3  in  the  modi-
ed  Centor  score)  should  ideally  be  submitted  to  culture  or
apid  antigen  detection  test  for  treatment  decision-making.
It  is  noteworthy  that  the  Modified  Centor  Criteria  only
ncludes  5 clinical  characteristics  of  S.  pyogenes  infections,
ot  including  other  important  features,  such  as  presence
f  palatal  petechiae,  sudden  symptom  onset,  absence  of
ral  ulcers  or  vesicles,  presence  of  headache,  absence  of
iarrhea,  nausea  and  vomiting,  among  other  findings.  Thus,
ore  important  than  just  evaluating  the  final  score  of  Mod-
fied  Centor  Criteria,  it  is  necessary  to  consider  the  overall
linical  picture  so  that  we  can  improve  the  sensitivity  and
pecificity  of  the  clinical  diagnosis  of  pharyngotonsillitis
aused  by  S.  pyogenes.
Other  tests  such  as  whole  blood  count  and  C-reactive
rotein  (CRP)  measurement  are  not  specific  to  differentiate
n  infection  caused  by  S.  pyogenes  from  other  infections.
owever,  viral  pictures  usually  occur  with  lymphocytosis  and
ow  levels  of  CRP,  whereas  bacterial  pictures  may  show  neu-
rophilia  and  higher  CRP  levels.  Similarly,  measurement  of
erum  anti-streptolysin  O  (ASLO)  levels  is  not  useful  for  the
iagnosis  of  acute  infection,  since  detection  in  serum  occurs
nly  after  the  first  week  of  infection,  peaks  between  the  4th
nd  6th  weeks,  and  may  remain  elevated  for  months  after
he  infection.
reatment
here  is  great  variability  regarding  the  disease  manage-
ent  recommendations  among  the  several  international
onsensuses,  especially  regarding  the  treatment  of  bacte-
ial  forms.35 Decades  ago,  it  was  believed  that  antibiotic
se  would  be  beneficial  for  all  bacterial  forms,  aiming  to
bbreviate  the  odynophagia  and  fever  symptoms.  However,
ven  in  cases  of  bacterial  pharyngotonsillitis,  most  of  them
r
a
c
b≥4  points  ∼50--60%
90%  of  cases)  show  complete  and  spontaneous  resolution
ithin  7  days.
Recent  meta-analysis  studies  have  shown  that  the  use
f  antibiotics  in  bacterial  cases  actually  shortens  the  dura-
ion  of  pain  and  significantly  reduces  the  risk  of  developing
heumatic  fever  in  more  than  2/3  cases  (RR  = 0.22;  95%
I  =  0.02--2.08).  Similarly,  it  reduces  the  chance  of  devel-
ping  AOM  (RR  =  0.30,  95%  CI  =  0.15--0.58),  ABRS  (RR  =  0.48,
5%  CI  =  0.08--2.76)  and  peritonsillar  abscess  (RR  =  0.15,
5%  CI  =  0.05--0.47)  when  compared  with  placebo.  How-
ver,  the  pain  improvement  promoted  by  the  antibiotic
s  very  discrete,  of  around  16  h  only,  so  the  NNT  is
ery  high,  not  justifying  its  use  as  a  generalized  primary
urpose  in  pain  control  or  in  the  prevention  of  suppura-
ive  complications.36,37 Thus,  despite  certain  divergences
etween  different  international  recommendations,  there  is
vidence  recommending  the  systematic  treatment  of  all
ases  of  pharyngotonsillitis  caused  by  S.  pyogenes,  due  to
ts  good  cost-benefit  ratio  for  the  primary  prevention  of
heumatic  fever.
Thus,  not  every  case  of  bacterial  pharyngotonsillitis
hould  be  treated  with  antibiotics,  except  the  most  severe
ases  or  cases  of  S.  pyogenes  etiology.  It  is  worth  mentioning
hat  the  treatment  related  to  rheumatic  fever  prevention
oes  not  need  to  be  implemented  early  (safety  of  up  to
 days  to  the  beginning  of  the  treatment),  which  allows
he  doctor  to  follow  the  patient’s  symptom  evolution  with-
ut  making  rushed  decisions,  or  until  the  results  of  exams
equested  to  complete  the  diagnosis  and  introduce  the
ntibiotic  are  obtained.  Table  8  summarizes  the  main  clini-
al  conditions  in  which  the  use  of  antibiotics  is  indicated  in
acterial  pharyngotonsillitis.
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Table  8  Antibiotic  use  indications  in  bacterial
pharyngotonsillitis.
Infections  caused  by  S.  pyogenes  in  regions  where  the  risk
of rheumatic  fever  is  high
Presence  of  peritonsillar,  parapharyngeal  or
retropharyngeal  abscess
Very  intense  pain
Poor  general  status  or  toxemia
Presence  of  septic  shock  signs
Presence  of  dyspnea  or  stridor
Signs  of  dehydration
Severe  comorbidities,  such  as  decompensated  diabetes  and
immunosuppression
Patients without  improvement  or  worsening  while  using
symptomatic  treatment
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cSome  pharyngotonsillitis  caused  by  unusual  agents,  such  as
C. diphtheriae,  N.  gonorrhoeae  or  Francisella  tularensis
Regarding  the  use  of  antibiotics  directed  to  S.  pyogenes
infections,  phenoxymethylpenicillin  (Penicillin  V)  or  ben-
zathine  penicillin  are  considered  the  drugs  of  choice.38
Another  good  therapeutic  option,  considered  by  some  guide-
lines  as  the  first-choice  drug,  is  amoxicillin  at  the  dose  of
50  mg/kg/day  divided  into  3  oral  doses,  for  10  days.  It  should
be  remembered  that  treatment  with  this  drug  for  7  days
may  not  be  effective  in  rheumatic  fever  primary  prevention,
because  it  does  not  eradicate  S.  pyogenes  from  the  orophar-
ynx.  In  case  of  patients  allergic  to  penicillins,  clarithromycin
or  erythromycin  can  be  used.39,40 In  case  of  therapeutic
failure  with  natural  and/or  synthetic  penicillins,  first-
generation  cephalosporins  or  clindamycin  can  be  used.  In
some  cases  of  bacterial  pharyngotonsillitis  with  a  presenta-
tion  that  is  not  characteristic  of  S.  pyogenes,  the  possibility
of  other  bacteria,  such  as  Group  C  and  G  Streptococcus,
H.  influenzae, Moraxella  catarrhalis, S.  aureus, Neisseria
gonorrhoeae,  Fusobacterium  nucleatum  +  Borrelia  vincentii
(Plaut-Vincent  angina)  must  be  considered.  In  those  situa-
tions,  when  antibiotics  are  required,  those  with  a  broad
coverage  spectrum  should  be  used,  such  as  amoxicillin,
amoxicillin-clavulanate  or  third-generation  cephalosporins
(Table  9).  Fig.  6  summarizes  the  algorithm  for  the  treatment
of  acute  pharyngotonsillitis.
Discussion
The  abusive  and  indiscriminate  use  of  antibiotics  on  a  global
scale  has  led  to  a  growing  concern  in  all  health  area  sectors.
We  are  on  the  verge  of  experiencing  a  new  era  where  banal
infections  can  no  longer  be  treated  with  antibiotics.41
Aiming  to  reverse  this  process,  the  WHO  has  started  an
intensive  information  campaign  to  reduce  the  risk  of  antibi-
otic  resistance,  and  several  countries  have  used  guidelines,
campaigns  and  even  public  health  policies  to  reduce  inap-
propriate  antibiotic  prescription,  including  Brazil,  where
antibiotics  have  only  been  sold  under  medical  prescription
since  2011.  These  measures  were  responsible  for  the  imme-
diate  reduction  in  the  sale  of  antibiotics  in  the  country,  but
as  early  as  March  2012,  the  records  indicated  that  antibiotic
sales  were  similar  to  those  prior  to  the  Regulations  (around
8.7  million  cases  only  in  that  month).42,43 Other  measures
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ave  been  carried  out  by  the  Federal  Government,  such  as
nformation  provided  to  the  population  by  ANVISA.  However,
hese  measures  are  modest  and  have  shown  limited  impact
t  national  level.
In  Brazil,  there  are  also  no  studies  that  recorded  the
nnual  use  of  antibiotics,  much  less  the  diagnosis  that  led
he  physician  to  prescribe  the  drugs.  Identifying  the  reasons
hy  physicians  prescribe  antibiotics  inappropriately  is  the
rst  step  toward  an  adequate  intervention.4,44--48
First,  the  indiscriminate  use  of  antibiotics  is  related  to
he  health  professionals  themselves  and,  second,  to  the
atients.45 It  is  a  concern  that  most  of  these  protagonists
o  not  show  having  knowledge  about  this  important  threat
nd  dramatic  reality  of  the  abusive  use  of  antibiotics.
Among  the  main  reasons  related  to  the  prescribing
hysician  are:  years  of  practice,  technical  inexperience  of
he  management  of  infectious  diseases,  complacency  with
uidelines  and  regulations  and,  especially,  fear  --  either
f  losing  the  patient  or  having  the  patient  develop  any
omplications  (which  are  known  not  be  prevented  by  the
se  of  antibiotics).
Even  in  developed  countries,  such  as  the  US  and  Canada,
t  is  estimated  that  approximately  30--50%  of  prescribed
ntibiotics  are  not  in  accordance  with  international  recom-
endations.  In  Brazil  and  Latin  America  as  a  whole,  there
re  no  data  on  inadequate  antibiotic  use.  However,  it  is
elieved  that  the  reality  of  Latin  America  is  similar  to  that  of
astern  Europe,  where  the  amount  of  prescribed  antibiotics
s  even  more  alarming.49 As  such  findings  are  not  restricted
o  developing  or  underdeveloped  countries,  it  is  believed
hat  behavioral  aspects  are  even  more  determinant  than  the
ultural  level  of  the  society.50 Overall,  there  is  a consensus
hat  it  is  a  complex  context  where  aspects  related  to  the
istory  of  professional  training  and  prescription  habits  are
ery  important  and  difficult  to  change.51 These  conclusions
re  consistent  with  a  society  where  the  culture  of  fear,  the
ractice  of  defensive  medicine  against  lawsuits  and  even  the
xpectation  of  faster  cure  using  some  type  of  medication,
utweigh  the  scientific  knowledge.
In  one  of  the  most  successful  international  examples
f  a campaign  for  the  rational  use  of  antibiotics,  Sweden
as  been  able  to  reduce  the  number  of  antibiotic  prescrip-
ions  associated  with  an  outpatient  visit  to  318  per  1000
nhabitants  by  2016.52 This  number  represents  about  a  dif-
erence  of  almost  40%  less  in  antibiotic  prescriptions  when
ompared  to  US  numbers.  Still  in  Sweden,  the  number  of
ntibiotic  prescriptions  for  acute  otitis  media  decreased  by
0%  from  2000  to  2005,  and  even  maintained  gradual  reduc-
ions  to  the  present  day.  It  should  be  noted  that  there  are
o  records  in  this  country  of  an  increase  in  suppurative
omplications,  such  as  mastoiditis,53 demonstrating  that  one
f  the  conditions  to  attain  success  in  this  campaign  was  to
onvince  physicians  and  patients  that  the  non-prescription
f  antibiotics  for  most  cases  of  AOM  is  not  related  to  the
ncrease  in  suppurative  complications.  This  reduction  in  pre-
criptions  was  achieved  in  Sweden  through  interventions
n  prescriptions  deemed  inappropriate,  either  through  edu-
ational  measures  for  physicians  and  patients,  continuing
ducation  for  physicians,  support  for  rapid  diagnosis  and
linical  decision-making,  and  by  convincing  doctors  to  pre-
cribe  antibiotics  ‘‘in  case  of  symptom  worsening’’,  the
o-called  ‘‘delayed  prescription’’.4,54
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Table  9  Main  antibiotics  used  in  bacterial  pharyngotonsillitis.
Antibiotic  agent  Dose  and  posology  Time  of
treatment
Observations
Indications  for  suspected  or  confirmed  infection  by  S.  pyogenes
Penicillin  Benzathine  <27  kg:  600,000  IU,  IM,  single  dose
>27  kg:  1,200,000  IU,  IM,  single  dose
Single  dose  Drug  of  choice
Phenoxymethylpenicillin
(Penicillin V)
<12  years:  90,000  IU/  kg  weight/day,  orally,
8/8 h
>12  years:  200,000--500,000  IU,  orally,  8/8  h
10  days  Drug  of  choice
Amoxicillin  ≤30  kg:  50  mg/kg  weight/day,  orally,  8/8  h
>30  kg:  500  mg,  orally,  8/8  h  or  875  mg,
orally,  12/12  h
10  days  Drug  of  choice
Clarithromycin  Children:  15  mg/kg  weight/day  (maximum
250  mg/dose),  orally,  12/12  h
Adults:  250  mg,  orally,  12/12  h  or  500  mg
(prolonged  release  drug),  orally,  1×/day.
10  days  Indicated  in  the
presence  of  allergy  to
penicillins
Erythromycin  Children:  30--50  mg/kg  weight/day  (up  to
500  mg/dose),  orally,  6/6  h
Adults:  500  mg,  orally,  6/6  h
10  days  Indicated  in  the
presence  of  allergy  to
penicillins
Cefadroxil  Children:  25--50  mg/kg  weight/day,  orally,
12/12  h
Adults:  500  mg,  orally,  12/12  h
10  days  Indicated  in  therapeutic
failure  with  penicillins
Cefalexin Children:  25--50  mg/kg  weight/day  (up  to
500  mg/dose),  orally,  6/6  h
Adults:  500  mg,  orally,  6/6  h
10  days  Indicated  in  therapeutic
failure  with  penicillins
Clindamycin  Children:  20--40  mg/kg  weight/day,  orally,
8/8 h,  up  to  300  mg/dose
Adults:  300--600  mg,  orally,  8/8  h
10  days  Indicated  in  therapeutic
failure  with  penicillins
Indications  for  other  infectious  agents
Amoxicillin  ≤30  kg:  50  mg/kg  weight/day,  orally,  8/8  h
>30  kg:  500  mg,  orally,  8/8  h  or  875  mg,
orally,  12/12  h
10  days
Cefuroxime  Children:  20  mg/kg  weight/day,  up  to
250 mg/dose,  orally,  12/12  h
Adults:  500  mg/dose,  orally,  12/12  h
10  days
Amoxicillin-clavulanate  ≤30  kg:  50  mg/kg  weight/day  (dose  related
to amoxicillin),  orally,  8/8  h
>30  kg:  500/125  mg,  orally,  8/8  h  or
875/125  mg,  orally,  12/12  h
10  days
Ceftriaxone  Children:  50--80  mg/kg  weight/day,  IV  or
IM,  1×  a  day
Adults:  1--2  g/day,  IV  or  IM,  1×  a  day
7  days
Indications  in  suppurative  complications
Amoxicillin-clavulanate  ≤30  kg:  50  mg/kg  weight/day  (equivalent
dose  of  amoxicillin),  orally  or  IV,  8/8  h
>30 kg:  500/125  mg,  orally,  8/8  h;
875/125  mg,  orally,  12/12  h;  500/100  mg  to
1000/200  mg,  IV,  8/8  h
10--14  days
Clindamycin  Children:  20--40  mg/kg  weight/day,  orally
or IV,  8/8  h
Adults:  300--600  mg/dose,  orally  or  IV,  8/8  h
10--14  days
Clindamycin  +  Ceftriaxone  Clindamycin,  IV  or  orally,  8/8  h:
Children:  20--40  mg/kg  weight/day  or
Adults:  300--600  mg/dose  +  Ceftriaxone,  IV
or IM,  1×  a  day.
Children:  50--80  mg/kg  weight/day  or
Adults  1--2  g/day
10--14  days
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Finally,  educating  the  general  population  has  been  con-
sidered  a  key  factor,  so  they  can  request  antibiotics  only
when  they  are  really  feel  the  need  for  them.  In  this  sense,
the  practice  of  delayed  prescription,  in  which  the  doctor
prescribes  the  medication  ‘‘in  case  the  patient  really  shows
symptom  worsening’’,  has  reduced  the  number  of  antibi-
otic  purchases.47,48 However,  for  that  to  occur,  the  patients
should  be  well  advised  on  the  negative  consequences  of
antibiotic  use,  either  for  the  patient  or  for  the  general
population.  For  instance,  by  telling  patients  that  the  risk
of  negative  consequences  due  to  antibiotic  use  is  much
greater  than  the  chance  of  complications  due  to  upper  air-
way  bacterial  infections.  Alone,  without  contextualization
and  education,  this  measure  has  little  positive  repercussion.
We  urgently  need  to  reduce  the  alarming  levels  of  unnec-
essary  antibiotic  prescriptions  for  upper  airway  infections
(50%)  as  this  practice  has  negative  impacts  on  the  patients
(increasing  the  chances  of  side  effects),  on  the  health  sys-
tem  (increasing  the  costs  of  our  prescriptions)  and  on  the
general  population  (considerably  increasing  antibiotic  resis-
tance).
More  than  ever,  it  is  necessary  to  reverse  this  situation,
and  for  that  purpose  we  need  that  ALL  (doctors,  patients,
pharmaceutical  industry,  government,  health  systems,  etc.)
modify  their  actions  and  behaviors,  with  the  common  objec-
tive  of  providing  a  more  precise  and  more  conscious  medical
care  to  our  population.
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